STOCK TITAN

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Roivant (ROIV) has announced it will host a conference call and webcast on Tuesday, November 12, 2024, at 8:00 a.m. ET to discuss its financial results for the second quarter ended September 30, 2024, along with a business update. Interested participants can register online for the phone conference, and presentation materials will be accessible through the Investors section of Roivant's website. The webcast recording will be available for later viewing on the company's website.

Roivant (ROIV) ha annunciato che ospiterà una conferenza telefonica e una trasmissione in webcast il martedì 12 novembre 2024, alle 8:00 a.m. ET per discutere i suoi risultati finanziari per il secondo trimestre chiuso il 30 settembre 2024, insieme a un aggiornamento sulla gestione. I partecipanti interessati possono registrarsi online per la conferenza telefonica, e i materiali della presentazione saranno accessibili attraverso la sezione Investitori del sito web di Roivant. La registrazione del webcast sarà disponibile per la visione successiva sul sito web della società.

Roivant (ROIV) ha anunciado que llevará a cabo una conferencia telefónica y una transmisión por web el martes 12 de noviembre de 2024, a las 8:00 a.m. ET para discutir sus resultados financieros del segundo trimestre que finalizó el 30 de septiembre de 2024, junto con una actualización empresarial. Los participantes interesados pueden registrarse en línea para la conferencia telefónica, y los materiales de la presentación estarán disponibles en la sección de Inversores del sitio web de Roivant. La grabación del webcast estará disponible para su visualización posterior en el sitio web de la empresa.

Roivant (ROIV)2024년 11월 12일 화요일 오전 8:00 ET에 전화 회의 및 웹캐스트를 개최하여 2024년 9월 30일 종료된 두 번째 분기 재무 결과 및 비즈니스 업데이트에 대해 논의할 것이라고 발표했습니다. 관심 있는 참가자는 전화 회의에 온라인으로 등록할 수 있으며, 프레젠테이션 자료는 Roivant 웹사이트의 투자자 섹션을 통해 접근할 수 있습니다. 웹캐스트 녹음은 회사 웹사이트에서 후속 시청을 위해 이용 가능합니다.

Roivant (ROIV) a annoncé qu'il tiendrait une conférence téléphonique et un webcast le mardi 12 novembre 2024 à 8h00 ET pour discuter de ses résultats financiers pour le deuxième trimestre clos le 30 septembre 2024, ainsi qu'une mise à jour sur son activité. Les participants intéressés peuvent s'inscrire en ligne pour la conférence téléphonique, et les documents de présentation seront accessibles dans la section Investisseurs du site web de Roivant. L'enregistrement du webcast sera disponible pour visionnement ultérieur sur le site de l'entreprise.

Roivant (ROIV) hat angekündigt, dass am Dienstag, den 12. November 2024, um 8:00 Uhr ET eine Telefonkonferenz und ein Live-Webcast stattfinden werden, um die finanziellen Ergebnisse des zweiten Quartals, das am 30. September 2024 endete, sowie eine Geschäftsanpassung zu erörtern. Interessierte Teilnehmer können sich online für die Telefonkonferenz anmelden, die Präsentationsmaterialien werden im Investorenbereich der Website von Roivant zugänglich sein. Die Aufzeichnung des Webcasts wird später auf der Website des Unternehmens zum Ansehen bereitstehen.

Positive
  • None.
Negative
  • None.

BASEL, Switzerland and LONDON and NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 12, 2024, to report its financial results for the second quarter ended September 30, 2024, and provide a business update.

To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant’s website after the conference call.

About Roivant

Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis; and mosliciguat, an inhaled soluble sGC activator in development for pulmonary hypertension associated with interstitial lung disease, in addition to other clinical stage molecules. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information, www.roivant.com.

Roivant Forward-Looking Statements

This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.

Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about potential share repurchases, the clinical and therapeutic potential of our product candidates, the availability and success of topline results from our ongoing clinical trials and any commercial potential of our product candidates following applicable regulatory approvals. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Investors
Keyur Parekh
keyur.parekh@roivant.com

Media
Stephanie Lee
stephanie.lee@roivant.com


FAQ

When will Roivant (ROIV) report Q2 2024 earnings?

Roivant will report its Q2 2024 earnings on Tuesday, November 12, 2024, at 8:00 a.m. ET.

How can I access Roivant's (ROIV) Q2 2024 earnings call?

You can access the conference call by registering online through the provided link, or view the webcast through the Investors section of Roivant's website at investor.roivant.com.

What period will Roivant's (ROIV) upcoming earnings report cover?

The earnings report will cover Roivant's second quarter, which ended September 30, 2024.

Roivant Sciences Ltd. Common Shares

NASDAQ:ROIV

ROIV Rankings

ROIV Latest News

ROIV Stock Data

8.85B
503.26M
29.56%
79.44%
6.3%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
HAMILTON HM11